Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Cardiology
•
Preventive Cardiology
How do you decide between IL-1 inhibitors, azathioprine, and IVIG for steroid-dependent recurrent/incessant pericarditis?
Related Questions
How do you counsel patients with non-statin associated inflammatory myopathies about statin use?
What are some general thoughts you have on the clinical utility and value of high sensitivity troponin in patients when there is little clinical evidence for acute MI or acute decompensated heart failure, and lack of evidence to support non-ischemic myocardial injury?
For women with known autoimmune diseases, how do you approach ASCVD risk stratification when deciding to start a statin or aspirin for primary prevention?
How do you approach cardiovascular risk management in patients with rheumatic disease?
What is your target or goal lipoprotein (a) level for patients on PCSK9 inhibitors for either primary or secondary prevention?
When would you consider initiating patients with CAD and aortic stenosis on PCSK9 inhibitors (as an adjunct to statin therapy), given favorable findings in the FOURIER trial?
Have you begun to incorporate high dose IV iron infusions into your practice for patients newly started on hemodialysis with TSAT < 30% and ferritin < 400 to reduce risk for non-fatal CV events based on findings from the PIVOTAL trial?
Would you consider opting for beta blocker withdrawal to improve exercise capacity in patients with heart failure with preserved ejection fraction and chronotropic incompetence?
Is bupropion, for tobacco cessation, safe in patients with a history of childhood seizures (either isolated or childhood epilepsy)?
How would you further risk stratify patients with systemic vasculitides and chest pain with atypical features?
